A021602 Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

January 19, 2021
https://www.clinicaltrials.gov/ct2/show/NCT03375320
Cancer - Pancreatic
Principal Investigator: Ding Wang, MD
cancer, pancreatic, pancreatic cancer, neuroendocrine
Accepting Participants